ATHENS, Ga.--(BUSINESS WIRE)--ArunA Biomedical today announced that Steven Stice, Ph.D., co-founder, chief executive and chief scientific officer, will present a corporate update and participate on a panel at the 2018 BIO International Convention occurring June 4-7, 2018 in Boston, MA. On the panel, Dr. Stice will discuss the use of exosomes as a therapeutic for the treatment of central nervous system and neurodegenerative disorders. During the corporate presentation, Dr. Stice will address recent studies that showed the companies neural stem cell-derived extracellular vesicles improved functional recovery in two divergent animal models following ischemic stroke.
Details of the company presentation are as follows:
Title: Neural
Exosomes: The Next Generation of CNS Therapeutics
Date:
Monday, June 4, 2018
Time: 4:45-5:00pm ET
Location:
Theater 4
Details of the panel presentation are as follows:
Title: Harnessing
the Body's Regenerative Capabilities – Therapeutic Development from the
Clinic to Commercialization
Date: Tuesday, June 5, 2018
Time:
11:00-12:00pm ET
Location: Room 210B, Level 2, Boston
Convention and Exhibition Center
To schedule a meeting with ArunA’s management team at the Convention, send them a meeting request through the BIO One-on-One Partnering™ system or contact the team at tstice@arunabio.com.
Exosomes as Therapeutics
Since their discovery more than 30
years ago, extracellular vesicles — nanometer-sized cell-signaling
particles — have been increasingly found to play a role in intercellular
communication, capable of delivering functional proteins, mRNA
transcripts and miRNA to cells throughout the body. Exosomes have the
potential to target any cell in the body and as proved in ArunA’s
studies are capable of multiple administrations via IV and of crossing
the blood brain barrier non-invasively to reach the site of injury.
Exosomes have shown great promise as potential therapeutics and as
vehicles to carry drug payloads to the site of injury or disease.
About ArunA Biomedical
At ArunA Biomedical, we are the
experts in the design and scaling of neural-derived exosomes, developing
a new class of cell-free biologics and cell-mediated drug delivery
systems to treat CNS and neurodegenerative disorders. www.arunabio.com
